Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
BMC Complement Altern Med ; 13: 192, 2013 Jul 26.
Artigo em Inglês | MEDLINE | ID: mdl-23889893

RESUMO

BACKGROUND: The absence of commercialized vaccines and antiviral agents against dengue has made the disease a major health concern around the world. With the current dengue virus transmission rate and incidences, the development of antiviral drugs is of vital need. The aim of this project was to evaluate the possibility of developing a local medicinal plant, Phyllanthus as an anti-dengue agent. METHODS: Cocktail (aqueous and methanolic) extracts were prepared from four species of Phyllanthus (P.amarus, P.niruri, P.urinaria, and P.watsonii) and their polyphenolic compounds were identified via HPLC and LC-MS/MS analysis. MTS assay was then carried out to determine the maximal non-toxic dose (MNTD) of the extracts, followed by screening of the in vitro antiviral activity of aqueous cocktail extracts against DENV2 by means of time-of-addition (pre-, simultaneous and post-) using RT-qPCR. The differentially expressed proteins in the treated and infected cells were analysed with two dimensional gel electrophoresis experiments. RESULTS: Several active compounds including gallic acid, geraniin, syringin, and corilagen have been identified. The MNTD of both aqueous and methanolic extracts on Vero cells were 250.0 µg/ml and 15.63 µg/ml respectively. Phyllanthus showed strongest inhibitory activity against DENV2 with more than 90% of virus reduction in simultaneous treatment. Two-dimensional analysis revealed significantly altered levels of thirteen proteins, which were successfully identified by tandem MS (MS/MS). These altered proteins were involved in several biological processes, including viral entry, viral transcription and translation regulations, cytoskeletal assembly, and cellular metabolisms. CONCLUSIONS: Phyllanthus could be potentially developed as an anti-DENV agent.


Assuntos
Antivirais/farmacologia , Vírus da Dengue/efeitos dos fármacos , Dengue/virologia , Phyllanthus/química , Extratos Vegetais/farmacologia , Animais , Chlorocebus aethiops , Ácido Gálico/farmacologia , Glucosídeos/farmacologia , Humanos , Taninos Hidrolisáveis/farmacologia , Fenilpropionatos/farmacologia , Plantas Medicinais , Espectrometria de Massas em Tandem , Células Vero
2.
Toxicol Pathol ; 38(3): 452-71, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20305093

RESUMO

The rat has been the preferred rodent toxicology species since before regulatory requirements have been in place, and there exists in the pharmaceutical industry and the regulatory agencies a significant amount of historical data for the rat. The resulting experience base with the rat makes the possibility of replacing it with the mouse for regulated toxicology studies untenable for all but the most extreme circumstances. However, toxicologists are very familiar with the mouse as a model for chronic carcinogenicity studies, and there exist multiple preclinical mouse models of disease. The authors evaluated the use of the mouse for early in vivo toxicology signal generation and prioritization of small molecule lead compounds prior to nomination of a development candidate. In five-day oral gavage studies with three test agents in the mouse, the authors were able to identify the same dose-limiting toxicities as those identified in the rat, including examples of compound-mediated hemolysis as well as microscopic lesions in the alimentary canal, kidney, and pancreas. Performing early signal generation studies in the mouse allows for earlier assessment of the safety liabilities of small molecules, requires significantly less compound, and allows evaluation of more compounds earlier in the project's life cycle.


Assuntos
Modelos Animais de Doenças , Camundongos , Testes de Toxicidade/métodos , Animais , Antineoplásicos/toxicidade , Inibidores Enzimáticos/toxicidade , Masculino , Camundongos Endogâmicos C57BL , Ratos , Ratos Sprague-Dawley
3.
J Biol Chem ; 282(37): 27198-27203, 2007 Sep 14.
Artigo em Inglês | MEDLINE | ID: mdl-17652091

RESUMO

UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase (GlcNAc-1-phosphotransferase) mediates the first step in the synthesis of the mannose 6-phosphate recognition marker on acid hydrolases. The transferase exists as an alpha(2)beta(2)gamma(2) hexameric complex with the alpha- and beta-subunits derived from a single precursor molecule. The catalytic function of the transferase is attributed to the alpha- and beta-subunits, whereas the gamma-subunit is believed to be involved in the recognition of a conformation-dependent protein determinant common to acid hydrolases. Using knock-out mice with mutations in either the alpha/beta gene or the gamma gene, we show that disruption of the alpha/beta gene completely abolishes phosphorylation of high mannose oligosaccharides on acid hydrolases whereas knock-out of the gamma gene results in only a partial loss of phosphorylation. These findings demonstrate that the alpha/beta-subunits, in addition to their catalytic function, have some ability to recognize acid hydrolases as specific substrates. This process is enhanced by the gamma-subunit.


Assuntos
Hidrolases/metabolismo , Transferases (Outros Grupos de Fosfato Substituídos)/química , Animais , Encéfalo/enzimologia , Catálise , Catepsina D/metabolismo , Lisossomos/enzimologia , Manose/metabolismo , Camundongos , Oligossacarídeos/metabolismo , Fosforilação , Subunidades Proteicas , Especificidade por Substrato , Transferases (Outros Grupos de Fosfato Substituídos)/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...